Arca
Skip to content
Tools
Tools

Fibrinogen

Complex in Homo sapiens that 5 drugs act on.

  • Drugs that act on it: 5
  • Approved: 1
  • In phases 1 to 3: 4
  • Sponsors: 3
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on FGA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 1
  • Other 4

Approved1

  • Fibrinolysin, human

Phase 34

  • Plasminogen
  • Fibrinogen, human
  • Ancrod
  • Alfimeprase

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • ARCA Biopharma, Inc.120%
      • Corza Medical GmbH120%
      • Jiangsu Jingze Biopharmaceutical Co., Ltd.120%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 5 act as: Fibrinogen hydrolytic enzyme; the rest name their own mechanism.
      Fibrinolysin, humanApprovedJiangsu Jingze Biopharmaceutical Co., Ltd.OtherInhibitorFibrinogen inhibitor1
      PlasminogenPhase 3—OtherHydrolytic enzyme96
      Fibrinogen, humanPhase 3Corza Medical GmbHOtherExogenous proteinFibrinogen exogenous protein11
      AncrodPhase 3—OtherHydrolytic enzyme1
      AlfimeprasePhase 3ARCA Biopharma, Inc.Protein or peptideHydrolytic enzyme0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 18 in all, from ClinicalTrials.gov.
      Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling DeficitsPlasminogenPhase 3RecruitingShandong Provincial HospitalNov 18, 2026
      Dose Reduced Alteplase in Managing Intrapleural SepsisPlasminogenPhase 3Not yet recruitingVanderbilt University Medical CenterNov 17, 2026
      Pneumatic Displacement With Anti-VEGF and Concomitant rtPA for PCV-related Submacular HemorrhagePlasminogenPhase 4Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineNov 17, 2026
      Stereotactic Aspiration Combined With Tenecteplase for Acute Pontine HemorrhagePlasminogenNot applicableRecruitingBeijing Tiantan HospitalNov 16, 2026
      Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 HoursPlasminogenPhase 3Not yet recruitingThe First Affiliated Hospital of University of Science and Technology of ChinaNov 12, 2026
      Effectiveness and Safety of TachoSil® Fibrin Sealant Patch for Supporting Dural Sealing Among Adult InpatientsFibrinogen, human—RecruitingCorza Medical GmbHNov 10, 2026
      Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk FeaturesPlasminogenPhase 3Not yet recruitingChina National Center for Cardiovascular DiseasesNov 4, 2026
      Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 HoursPlasminogenPhase 3Not yet recruitingFujian Medical University Union HospitalNov 3, 2026
      A Study Evaluating the Efficacy and Safety of Recombinant Human Truncated Plasmin Injection (JZB32) in Patients With Vitreomacular TractionFibrinolysin, humanPhase 2RecruitingJiangsu Jingze Biopharmaceutical Co., Ltd.Nov 2, 2026
      INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632PlasminogenPhase 3Not yet recruitingUniversity of CalgaryOct 30, 2026
      Stability of Blood Clotting Products Stored in Emergency Ambulances Under Real-World ConditionsFibrinogen, human—RecruitingMedical University of GrazJun 15, 2026
      Clinical Study on the Safety and Efficacy of Tendon Stem Progenitor Cells Therapy for Rotator Cuff TearsFibrinogen, humanEarly phase 1Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineJan 6, 2026
      Fibrinogen in Liver TransplantFibrinogen, humanPhase 4RecruitingTrauma Hemostatis and Oxygenation Research (THOR) NetworkDec 5, 2025
      NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base SurgeryFibrinogen, humanNot applicableRecruitingMaria Sklodowska-Curie National Research Institute of OncologyOct 14, 2025
      PS-002 for the Treatment of IgA Nephropathy in AdultsFibrinogen, humanPhase 1 / Phase 2RecruitingPurespring Therapeutics LimitedSep 19, 2025
      Characterization and Longitudinal Monitoring of Muscular Phenotype in Patients Admitted to Intensive Care for SepsisFibrinogen, humanNot applicableRecruitingCentre Hospitalier de Saint-BrieucJul 20, 2025
      Social Needs Screening and Chronic Diseases Study (WE CARE)AncrodNot applicableRecruitingUniversity of Massachusetts, WorcesterApr 1, 2025
      Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry EyeFibrinogen, humanPhase 3Not yet recruitingCambium Bio LimitedMar 31, 2025

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364709, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.